Andreas Ladurner

Company: Eisbach Bio

Job title: Chief Scientific Officer, Co-Founder & Co-Managing Director

Seminars:

Allostery Enables Transformative Translation through ALC1 Inhibition 11:00 am

Leveraging allosteric inhibition in the DDR space towards safer therapies  Demonstrating that the allosteric small molecule ALC1 inhibitor EIS-12656 disrupts chromatin remodeling and exploits vulnerabilities in HR-deficient tumors  Exceptional preclinical safety with monotherapy efficacy and potentiation of DDR therapies  Highlighting exceptional preclinical safety with monotherapy efficacy and potentiation of DDR therapies, outlining the drug’s translational…Read more

day: Day Two